Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 16/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 15/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | TESK1 | Q15569 | 1/20 | 0.31 |
| ▸ | TESK2 | Q96S53 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870039 | 0.90 | LIMK1 (0.38) | LIMK1LIMK2MAPK14CHRNB2CHRNA4 | |
| SCHEMBL4019011 | 0.86 | LIMK1 (0.36) | LIMK1LIMK2TESK1TESK2 | |
| SCHEMBL4019009 | 0.84 | LIMK1 (0.36) | LIMK1LIMK2TESK1TESK2 | |
| SCHEMBL5748048 | 0.78 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL4019003 | 0.77 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL4017708 | 0.77 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL4018434 | 0.77 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL4026657 | 0.77 | ADAMTS5 (0.36) | LIMK1LIMK2TESK1TESK2 | |
| SCHEMBL4026653 | 0.74 | LIMK1 (0.33) | LIMK1LIMK2TESK1TESK2 | |
| SCHEMBL4503015 | 0.71 | PDE2A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | claimed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | claimed |
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | DPYD, ABCC1, ARF5 | LIMK1 2268/4885LIMK2 1660/4885MAPK14 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.